HZNP - ホライゾン・ファ―マ （Horizon Pharma plc） ホライゾン・ファ―マHZNPのチャート
HZNPの企業情報
| symbol | HZNP |
|---|---|
| 会社名 | Horizon Pharma Plc （ホライゾン・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ホライゾン・ファーマ(Horizon Pharma Public Limited Company)はバイオ医薬品会社である。同社は満たされていない医療ニーズに対処する差別化された接近可能な医薬品の特定・開発・取得・商業化に従事する。同社は希少疾病、リウマチ、プライマリケア事業セグメントを通じて11の医薬品を販売する。同社が販売する医薬品は、ACTIMMUNE（インターフェロンγ-1b）、BUPHENYL（フェニル酪酸ナトリウム）錠剤および粉末、DUEXIS（イブプロフェン/ファモチジン）、KRYSTEXXA（ペグロチナーゼ）、MIGERGOT（エルゴタミン酒石酸塩およびカフェイン坐剤）、2重量％のPENNSAID（ジクロフェナクナトリウム局所溶液）、またはPENNSAID 2％、PROCYSBI（酒石酸水素システアミン）遅延放出カプセル、QUINSAIR（エアロゾル化形態のレボフロキサシン）、RAVICTI（グリセロールフェニルブチラート）経口液体、RAYOS （プレドニゾン）遅延放出錠剤およびVIMOVO（ナプロキセン/エソメプラゾールマグネシウム）を含む。 ホライゾン・ファ―マはアイルランドのバイオ医薬品持株会社。関節炎、疼痛、炎症性疾患向けの医薬品を開発、販売する。主要製品はイブプロフェンとファモチジンを組み合わせた単一錠剤のDUEXIS、成人向けの関節リウマチ治療薬RAYOS/LODOTRA(米国内でRAYOS、米国外ではLODOTRAとして提供)、およびVIMOVOなど。 Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives. |
| 本社所在地 | Connaught House 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 IRL |
| 代表者氏名 | Timothy P. Walbert ティモシー・P・ウォルバーツ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +353 1-772-2100 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 1010人 |
| url | www.horizonpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/hznp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 89.14000 |
| 終値（lastsale） | 18.16 |
| 時価総額（marketcap） | 3025996042.08 |
| 時価総額 | 時価総額（百万ドル） 3177.629 |
| 売上高 | 売上高（百万ドル） 172.581 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4352.536 |
| 当期純利益 | 当期純利益（百万ドル） -375.58200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Horizon Pharma PLC revenues increased 3% to $526.7M. Net loss decreased 37% to $190.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing val decrease of 78% to $37.3M (expense) Interest Expense - Net decrease of 3% to $61.5M (expense). |
HZNPのテクニカル分析
HZNPのニュース
Seven Days To Go (NASDAQ:HZNP) 2023/02/02 14:05:40 Seeking Alpha
Hi everyone,This is a reminder that on February 9, 2023, I will increase the price of the Growth Stock Forum from $299 per year to $399 per year and from $35 per month to $55 per month.If…
Horizon Therapeutics confirms FTC Second Request in Amgen deal 2023/01/31 21:24:07 Seeking Alpha
Horizon Therapeutics (HZNP) and Amgen (AMGN) confirmed the companies received a "Second Request" from the Federal Trade Commission in regards to the planned almost $28 billion…
Analyst Says Selecta Biosciences'' Gout Candidate Can Potentially Raise The Bar On Several Fronts 2023/01/31 18:15:48 Benzinga
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB ) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout. The analyst expects positive top-line data in 1Q23 for SEL-212. While many will likely compare the results to Horizon Therapeutics PLC ''s (NASDAQ: HZNP ) Krystexxa and the various immunomodulating combinations, Canaccord sees SEL-212 as a step ahead in the gout treatment paradigm. The once-a-month treatment sets it apart from Krystexxa. The analyst anticipates a 40-50% … Full story available on Benzinga.com
Where Do Analysts Think The Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Is Going 2023/01/31 17:00:00 Stocks Register
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) price is hovering lower on Tuesday, January 31, dropping -0.34% below its previous close. A look at today’s price movement shows that the recent level at last check reads $110.05, with intraday deals fluctuating between $110.04 and $110.94. The company’s 5Y monthly beta was ticking 1.18 while its P/E … Where Do Analysts Think The Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Is Going Read More »
Horizon Therapeutics ticks lower on report of FTC 2nd request in Amgen deal 2023/01/31 15:25:05 Seeking Alpha
Horizon Therapeutics (HZNP) ticked down 0.3% on a report that Amgen (AMGN) received a so-called 2nd request from the Federal Trade Commission in regards to its planned almost $28…
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) 2022/09/29 12:00:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inflammatory signs and symptoms that are often associated with TED.1 Topline results are expected in the second quarter of 2023. TED is a serious,
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) 2022/09/29 12:00:00 Wallstreet:Online
Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inflammatory signs and symptoms that are often associated with TED.1 Topline
Tuesday’s Top Analyst Upgrades and Downgrades: Bristol-Myers, Costco, Exxon, FedEx, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags, Unity Software and More – 24/7 Wall St. 2022/09/27 12:50:06 24/7 Wall street
Tuesday''s top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.
Horizon pays HemoShear milestone payment under pact to develop gout therapies 2022/09/21 12:04:59 Seeking Alpha
Horizon Therapeutics (HZNP) said it paid a milestone payment to HemoShear Therapeutics for advancing product candidates against a second target to treat gout under their…
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame''s Patient Advocacy Initiative 2022/09/16 13:04:00 Finanz Nachrichten
Novel Program Supports Student Education and Future Careers in Patient Advocacy Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the Univ…
Horizon Therapeutics Delivers Upbeat Results in Q4; Shares Up 6.5% 2022/03/02 18:39:55 Smarter Analyst
Horizon Therapeutics (NASDAQ: HZNP) shares jumped 6.5% on March 1, after the biopharmaceutical company delivered stronger-than-expected fourth-quarter results. The post Horizon Therapeutics Delivers Upbeat Results in Q4; Shares Up 6.5% appeared first on Smarter Analyst .
Horizon Therapeutics Public Limited Company 2021 Q4 - Results - Earnings Call Presentation 2022/03/02 11:55:05 Seeking Alpha
Horizon Therapeutics PLC (HZNP) CEO Tim Walbert on Q4 2021 Results - Earnings Call Transcript 2022/03/01 17:13:03 Seeking Alpha
Horizon Therapeutics rises in premarket after earnings beat, 2022 guidance (HZNP) 2022/03/01 14:26:16 Seeking Alpha
Shares of Horizon Therapeutics (HZNP) are trading higher in the premarket session after its Q4 2021 results beat on the top and bottom lines and it issued 2022 guidance.
Horizon Therapeutics'' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales 2022/03/01 14:17:21 Benzinga
Horizon Therapeutics plc''s (NASDAQ: HZNP ) Q4 sales increased 36% Y/Y to $1.014 billion , beating the consensus of $995.87 million. The adjusted gross profit declined slightly from 87.1% to 86.5%, with an adjusted EBITDA of $416.0 million, including $36.2 million of upfront and milestone payments primarily related to the collaboration agreement with Alpine. The Company reported an adjusted EPS of $1.41, up … Full story available on Benzinga.com